Graves病患者血清sCD8测定的临床意义

Clinical study on serum soluble CD8 antigen of patients with Graves disease

目的 :探讨Graves病患者血清可溶性CD8抗原 (sCD8)测定的临床意义。方法 :参照国外文献 ,建立了人血清sCD8测定的酶联免疫吸附实验 (ELISA)方法。测定 40例正常人及 46例GD患者血清sCD8含量并作动态观察。结果 :GD组治疗前血清sCD8水平显著高于对照组 ,经丙基硫氧嘧啶 (PTU)治疗 2～ 7月后 ,病情缓解者sCD8明显下降 ,与治疗前有显著性差异 (P <0 0 0 1) ,而未缓解者持高不降。血清sCD8与T3、T4、TSH、TGA、TMA均无相关性。结论 :血清sCD8水平与GD病情活动性有一定相关性 ,并可能对预后判断有价值。PTU显示免疫抑制作用。

Objective:To study the clinical value of serum soluble CD8 antigen (sCD8) in patients with Graves disease (GD).Methods:The level of serum sCD8 was detected by ELISA in 40 healthy controls and 46 GD patients.Serial measurement were carried out in 28 patients before and after treatment with PTU.Results:Serum sCD8 levels were increased significantly in untreated GD patients as compared with controls (21.91±9.13 kU/L vs 9.84±3.08 kU/L,P<0.001).After treatment with PTU for 2 to 7 months,sCD8 levels returned to normal when euthyroidism was established in 22 patients(9.67±5.14 kU/L) but remained high in 6 unimproved patients(38.74±9.89 kU/L).No statistical relationship was found between sCD8 and T3、T4、TSH、TGA、TMA.Conclusion:The level of serum sCD8 correlate well with disease activity and may be of value in disease prognosis.PTU show some suppressor effect on immune system.